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Abstract
Dysfunction of dopamine D3 receptors, particularly in the mesocorticolimbic system, has been linked to
the pathogenesis of major depression. Preclinical data show enhanced D3 receptor binding in the striatum
upon antidepressant medication and electroconvulsive therapy (ECT). Thus, the potential impact of
dopamine D3 receptor gene (DRD3) variation on ECT outcome in treatment-resistant major depression
was evaluated by applying a combined molecular and imaging genetic approach. Altogether, 10 rep-
resentative variants covering 95.4% of DRD3 gene variation were investigated for association with
response to ECT in a sample of 104 (71 female, 33 male) Caucasian patients with pharmacorefractorymajor
depression. Additionally, ventral striatum responsiveness to happy faces was assessed in two indepen-
dent samples of depressed patients (total N=54) by means of functional magnetic resonance imaging
at 3 T. Signiﬁcant association of DRD3 rs3732790, rs3773679 and rs9817063 variants with response
(uncorrected p=0.02–0.03) and remission (uncorrected p=0.01) after ECT was discerned. Logistic
regression analyses revealed association of rs3732790 (uncorrected p=0.009 ; corrected p=0.045) and
rs3773679 (uncorrected p=0.009 ; corrected p=0.045) with remission when applying a recessive model of
inheritance. The rs3732790T allele conferring a more favourable treatment response was furthermore
found to be associated with stronger striatal responsiveness to happy facial expressions (sample 1 : cluster-
corrected p=0.002 ; sample 2 : p=0.023). In summary, the present study suggests some impact of DRD3
gene variation on ECT response, potentially mediated by alteration of striatal engagement during the
processing of emotionally rewarding stimuli.
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Introduction
Major depression has been suggested to be crucially
mediated by a deﬁcit in the catecholaminergic system
including reduced dopaminergic neurotransmission
(see Nutt et al. 2006; Porcelli et al. 2011). Particularly,
anhedonia as a core symptom of major depression
appears to be driven by the mesocorticolimbic
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dopamine system (e.g. Shirayama & Chaki, 2006;
Stein, 2008) and has been found to be associated
with decreased responsiveness of – among others –
dopamine D3 receptors in the nucleus accumbens (for
a review see Beninger & Banasikowski, 2008).
The dopamine D3 receptor has furthermore been
proposed to be involved in the mediation of anti-
depressant treatment eﬀects, as antidepressant agents
such as tricyclics, selective serotonin reuptake in-
hibitors or serotonin–norepinephrine reuptake in-
hibitors lead to enhanced D3 receptor binding (Maj &
Rogo´z, 1999 ; Maj et al. 1998; Rogo´z & Dziedzieka-
Wasylewska, 1999). Also, direct agonism at the D3 re-
ceptor by pramipexole has been reported to exert a
mood-stabilizing and antidepressant eﬀect in animal
models of depression by reducing stress-induced an-
hedonia (Willner et al. 1994) and immobility time
during the forced swimming test (Maj et al. 1997).
Pramipexole has been suggested to also constitute
an eﬀective antidepressive agent in several clinical
studies of patients with major depression and
bipolar II disorder (Corrigan et al. 2000; Szegedi et al.
1996; Zarate et al. 2004) and patients with treatment-
resistant depression have been observed to beneﬁt
from an add-on therapy with pramipexole (Lattanzi
et al. 2002).
Electroconvulsive therapy (ECT) is one of the most
powerful antidepressant treatment strategies available
today. Although the exact mechanism of action is not
entirely known (cf. Merkl et al. 2009), ECT has been
reported to target the dopamine system (Mann, 1998)
and to enhance striatal D3 receptor binding in rodent
models of the normal as well as the Parkinsonian brain
(Strome et al. 2007). In rats, in response to repeated
electroconvulsive shock treatment, increased D3 re-
ceptor mRNA expression and enhanced D3 receptor
binding have been shown to occur particularly in the
shell of the nucleus accumbens, while D1 and D2 re-
ceptor mRNA levels in the shell of the nucleus ac-
cumbens were not changed by ECT (Lammers et al.
2000). The nucleus accumbens, as mentioned above,
has repeatedly been implicated in the pathogenesis of
depression (for review see Beninger & Banasikowski,
2008) and has been suggested as a promising treat-
ment target for deep brain stimulation in treatment-
resistant major depression explicitly increasing
hedonic activities (Bewernick et al. 2010; Schlaepfer
et al. 2008) Also, ECT has been shown to attenuate
the anhedonic eﬀects of amphetamine withdrawal
and to restore brain reward function in rats (Barr
et al. 2002). Therefore, D3 receptor expression might
constitute a neurobiological link in the mediation
of general antidepressant eﬀects, potentially via
enhanced responsiveness to the mesocorticolimbic
dopaminergic system (cf. Lammers et al. 2000; Willner,
1997).
The gene coding for the dopamine D3 receptor
(DRD3) located on chromosome 3q13.3 might thus be
considered a promising candidate in the molecular
and pharmacogenetic investigation of depression.
Although most studies available so far do not pro-
vide evidence for a direct involvement of DRD3 gene
variation in depression or its treatment (Benedetti
et al. 2003; Manki et al. 1996; Schumann et al. 2001;
Serretti et al. 1999, 2000), two studies suggested as-
sociation of the DRD3 Bal1 (Ser9Gly) polymorphism
(rs6280) with the categorical diagnosis of depression,
partly in interaction with stressors (Dikeos et al.
1999; Henderson et al. 2000). In a sample of patients
with bipolar disorder treated with a combination of
olanzapine and ﬂuoxetine, DRD3 single nucleotide
polymorphisms (SNPs) rs167770 and rs6280 have
been found to inﬂuence pharmacoresponse, particu-
larly regarding depressive symptoms (Perlis et al.
2010).
Therefore, in the present study we attempted to
elucidate two related questions. In the ﬁrst step, we
investigated the role of the dopamine D3 receptor gene
in the biological mechanism of electroconvulsive
treatment response by analysing a representative
selection of 10 DRD3 variants in a sample of 104
patients with pharmacologically treatment-resistant
major depression treated with ECT. In the second step,
we aimed to explore the neurobiological eﬀects of
those DRD3 genetic variants that yielded signiﬁcant
associations with ECT treatment response and re-
mission. For this purpose, two independent samples
of acutely depressed in-patients from previous studies
on emotion processing in depression using functional
magnetic resonance imaging (fMRI) were available.
These two samples were therefore genotyped for those
DRD3 SNPs that were signiﬁcantly associated with
ECT treatment response. While so far, to the best of
our knowledge, no study has investigated the impact
of DRD3 gene variation on neurobiological response
patterns, several previous imaging studies exploring
the eﬀect of other dopaminergic genes (e.g. DAT,
COMT, DRD4) consistently found strong genetic ef-
fects on ventral striatum responsiveness during the
processing of positive stimuli or reward (Aarts et al.
2010; Camara et al. 2010; Dreher et al. 2009; Forbes et al.
2009a, b ; Hahn et al. 2011; Kirsch et al. 2006; Krugel
et al. 2009; Schmack et al. 2008; Yacubian et al. 2007).
As stated above, this seems neurobiologically plaus-
ible since the ventral striatum/nucleus accumbens is
a crucial part of the mesolimbic dopamine reward
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system (Nestler & Carlezon, 2006). Several studies
have demonstrated that depressed patients show re-
duced striatal responsiveness to positive stimuli
(Epstein et al. 2006; Forbes et al. 2006; Lawrence et al.
2004; Pizzagalli et al. 2009a), which is apparently as-
sociated with anhedonia (see above and Forbes et al.
2009a, b ; Keedwell et al. 2005; Pizzagalli et al. 2009b).
Furthermore, it has already been shown that greater
pre-treatment reactivity of the striatum is associated
with stronger symptom reduction in depressed
patients after treatment (Forbes et al. 2010) and that an
increase in dopaminergic neurotransmission in the
striatum may account in part for the therapeutic eﬀect
of ECT in mood disorders (Landau et al. 2011). We
therefore speculated that carriers of protective DRD3
alleles associated with favourable ECT treatment out-
come would also show stronger striatal engagement
during the processing of positive stimuli (happy facial
expressions).
Method
Design and sample
A sample of 104 unrelated Caucasian patients with
severe pharmaco-resistant major depression (for clini-
cal and demographic data see Table 1) were consecu-
tively recruited at the Department of Psychiatry,
University of Muenster, Germany, between 2003
and 2008. Pharmacoresistance was deﬁned as pre-
treatment with at least two unsuccessful cycles of
antidepressant medication (mean duration of anti-
depressant treatment before current ECT treatment
6.1¡5.0 yr). All patients were admitted for in-patient
treatment due to the severity of illness, chronicity
of illness, psychosocial aspects or suicidality and re-
ceived ECT during the course of their in-patient
treatment. Patients with other Axis I disorders, such
as bipolar disorder, schizoaﬀective disorders, schizo-
phrenia, eating disorders or comorbid substance
abuse disorders, and signiﬁcant somatic disorders,
such as mental retardation, neurological or neuro-
degenerative disorders, were not included in this
analysis. Comorbidity with anxiety disorders except
for obsessive-compulsive disorder was allowed when
not constituting the primary diagnosis. Caucasian de-
scent was ascertained by Caucasian background
of both parents in order to minimize the risk of
ethnic stratiﬁcation. The study was approved by the
Ethics Committee of the University of Muenster,
Muenster, Germany. Written informed consent was
obtained after complete description of the study to the
subjects.
Assessment and treatment response/remission
Patients’ psychiatric diagnosis was obtained by the
use of a structured clinical interview (SCID-I) accord-
ing to DSM-IV criteria (Wittchen et al. 1997). Clinical
course of depression was assessed by clinically ex-
perienced psychiatrists using the Hamilton De-
pression Scale (HAMD-21) on a weekly basis from
admission throughout the course of treatment until
the end of ECT. The mean HAMD score at admission
was 24.6¡8.5. ECT was taken up in the course of
in-patient treatment (on average 27.4¡49.8 d after
admission), with a mean pre-ECT HAMD score of
22.9¡8.6 and a mean post-ECT HAMD score of
9.1¡6.9 (mean diﬀerence 13.7¡11.1, t=12.6, d.f.=
102, p<0.0005). Clinical response to ECT was assessed
using the HAMD-21 scores pre- and post-ECT (cf.
Domschke et al. 2009). While response to ECT was
deﬁned as a reduction of at least 50% on the HAMD-
21 score between pre-ECT and post-ECT measures,
remission after ECT was classiﬁed according to the
cut-oﬀ of 7 on the HAMD-21 scale (HAMD-21 change
pre- to post-ECT).
Electroconvulsive therapy
Brief pulse ECT was administered three times per
week with a 2-d interval (Monday–Wednesday–
Friday) in all patients using the Thymatron System-IV
system (Thymatron, Somatics Inc., USA) with a mean
total number of single ECT treatments of 14.2¡6.0.
The number of sessions within a course of ECT was
determined according to clinical response. The regular
course of ECT includes a total of 12 single sessions
within 4 wk. In case of insuﬃcient clinical response,
another six to 12 sessions were administered depend-
ing on clinical improvement. In order to obtain a
suﬃcient response to ECT, in most cases initial
stimulus intensity was determined by the modiﬁed
age method prior to the ﬁrst ECT treatment session
according to Abrams (2002). In cases of insuﬃcient
response [seizure activity <25 s according to electro-
encephalography (EEG)], restimulation and dose ti-
tration in 5–10% steps was carried out to increase
seizure activity. In the case of increased seizure
threshold throughout the course of ECT, stimulus
intensity was adapted in the same manner. For an-
aesthesia, thiopental was usually used; in case of side-
eﬀects or pre-existent cardiac disease, etomidate was
chosen. For muscle relaxation, succinylcholine was
administered. Physiological monitoring included a
two-lead EEG, single-lead electromyography, electro-
cardiography and blood pressure monitoring. All
patients received right unilateral ECT. In six patients,
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Table 1. Sociodemographic and clinical characteristics as well as DRD3 genotype distribution across response and remission status after electroconvulsive therapy (ECT) treatment
in 104 patients with major depression
Overall sample
(n=104)
Responders Remitters
Yes (n=72) No (n=32) p value* Yes (n=53) No (n=51) p value*
Age (yr¡S.E.) 56.6¡13.6 58.6¡1.7 53.1¡2.1 0.04 59.1¡1.7 54.1¡1.9 0.05
Gender (n ; %)
Male 33 ; 31.7 19 ; 28.4 14 ; 37.8 0.07 15 ; 28.3 18 ; 35.3 0.4
Female 71 ; 68.3 53 ; 71.6 18 ; 62.2 38 ; 71.7 33 ; 64.7
Age of onset (yr¡S.E.) 40.6¡14.6 41.7¡1.8 38.6¡2.4 0.31 42.3¡1.9 38.8¡2.1 0.23
Lifetime duration of depression (yr¡S.E.) 6.8¡6.9 5.8¡0.6 8.9¡1.7 0.02 5.1¡0.6 8.6¡1.2 0.009
Number of depressive episodes (n¡S.E.) 3.7¡3.0 3.4¡0.3 4.3¡0.7 0.21 3.2¡0.3 4.2¡0.5 0.10
Number of suicide attempts (n¡S.E.) 0.7¡1.1 0.7¡0.1 0.8¡0.2 0.85 0.7¡0.1 0.8¡0.2 0.67
Lifetime duration of antidepressant treatment
in yr (mean¡S.E.)
6.1¡0.5 5.4¡0.5 7.5¡1.0 0.04 4.7¡0.5 7.5¡0.8 0.003
Courses of ECT (mean¡S.E.) 1.6¡1.0 1.6¡0.1 1.6¡0.2 0.96 1.5¡0.1 1.7¡0.2 0.45
Duration of ECT treatments in wk (mean¡S.E.) 8.1¡4.5 8.2¡0.6 7.9¡0.7 0.72 8.2¡0.7 8.0¡0.6 0.86
Initial stimulation intensity (mean¡S.E.) 29.8¡3.1 30.7¡3.7 28.1¡5.7 0.68 30.8¡4.2 28.7¡4.6 0.73
HAMD admission (mean¡S.E.) 24.6¡8.5 26.8¡1.1 20.7¡1.1 0.0003 25.3¡1.2 23.9¡1.1 0.41
HAMD pre-ECT (mean¡S.E.) 22.9¡8.6 25.2¡1.1 18.5¡1.1 0.0001 23.2¡1.2 22.5¡1.2 0.64
HAMD post-ECT (mean¡S.E.) 9.1¡6.9 5.6¡0.5 15.5¡1.0 0.00005 3.9¡0.3 14.5¡0.8 0.00005
Concomitant antidepressants (N ; %)
SSRI 21 ; 20.2 15 ; 71.4 6 ; 28.6 0.45 11 ; 52.4 10 ; 47.6 0.88
SNRI 40 ; 38.46 27 ; 67.5 13 ; 32.5 0.61 22 ; 55.0 18 ; 45.0 0.52
NaSSA 45 ; 43.3 29 ; 64.4 16 ; 35.6 0.39 27 ; 60 18 ; 40 0.18
Tri-/tetracyclics 3 ; 2.9 2 ; 66.7 1 ; 33.3 0.93 2 ; 66.7 1 ; 33.3 0.58
Other 5 ; 4.8 4 ; 80.0 1 ; 20 0.31 2 ; 40 3 ; 60 0.51
Concomitant neuroleptics (n ; %) 83, 79.8 56 ; 67.5 27 ; 32.5 0.23 45 ; 54.2 38 ; 45.8 0.31
Concomitant anxiolytics (n ; %) 21, 20.2 16 ; 76.2 5 ; 23.8 0.20 12 ; 57.1 9 ; 42.9 0.49
DRD3 rs167770 (AA/AG/GG) 48/46/3 31/46/3 17/13/0 0.275 22/24/2 26/22/1 0.69
DRD3 rs1800828 (CC/CG/GG) 7/32/60 4/24/40 3/8/20 0.745 4/15/30 3/17/30 0.87
DRD3 rs324026 (CC/CT/TT) 9/42/45 5/32/29 4/10/16 0.247 5/23/20 4/19/25 0.592
DRD3 rs324035 (AA/AC/CC) 4/26/70 2/17/50 2/9/20 0.833 2/16/32 2/10/38 0.387
DRD3 rs3732790 (AA/AT/TT) 19/49/28 11/37/20 8/12/8 0.033 5/28/16 14/21/12 0.05
DRD3 rs3773679 (AA/AG/GG) 20/49/30 11/37/20 9/12/10 0.018 5/28/16 15/21/14 0.047
DRD3 rs6280 (CC/CT/TT) 9/46/43 5/34/28 4/12/15 0.472 5/24/19 4/22/24 0.691
DRD3 rs7638876 (CC/CT/TT) 10/44/46 6/33/30 4/11/16 0.49 6/23/21 4/21/25 0.657
DRD3 rs9817063 (CC/CT/TT) 24/55/21 14/42/13 10/13/8 0.016 7/34/9 17/21/12 0.022
HAMD, Hamilton Rating Scale for Depression ; SSRI, selective serotonin reuptake inhibitor ; SNRI, serotonin–norephinephrine reuptake inhibitor ; NaSSA, noradrenergic and
speciﬁc serotonergic antidepressant.
* Pearson x2-test for categorical variables and t test for continuous variables. Signiﬁcant p values at signiﬁcance levelf0.05 are shown in bold (not corrected for multiple testing).
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treatment was switched to bilateral ECT because of
insuﬃcient response to unilateral treatment. Al-
together, 74 patients (71.2%) received concomitant
antidepressant pharmacological treatment during
ECT, with 39 patients being treated with a combi-
nation of two to three antidepressants. The majority of
the patients received adjunct neuroleptic treatment
(79.8%) and 20.2%were co-medicated with anxiolytics
(see Table 1).
Selection of SNPs and genotyping
The present analysed sequence of the DRD3 gene
comprising about 50.3 kb between positions 113897899
and 113847557 at chromosome 3q13.3 contains 80 SNPs
with a minor allele frequency (MAF) >5% (Inter-
national HapMap Consortium, 2003). We used various
techniques to limit the number of SNPs, assessed to the
most relevant. We initially constructed the linkage
disequilibrium (LD) pattern of the Center for the study
of polymorphisms in humans (CEPH) population of
the HapMap Phase II genotype data to identify tagging
SNPs by an aggressive tagging approach (MAF>5%
and r2>0.8) using the Gevalt v. 2 software package
(Davidovich et al. 2007). Subsequently, we reduced
SNP numbers by assessing the ability of limited num-
bers of the tagging SNPs to predict the total SNP
population using the Stampa algorithm (Halperin et al.
2005). With this approach, 95.4% of the variation in the
gene was captured using 10 tagging SNPs (rs167770,
rs1800828, rs324026, rs324028, rs324035, rs3732790,
rs3773679, rs6280, rs7638876, rs9817063). The mean r2
of individual tagging SNPs in conjunction with one or
more tagged SNPs was 0.988.
Genotyping was carried out following published
protocols applying the multiplex genotyping assay
iPLEXTM for use with the MassARRAY platform (Oeth
et al. 2007), yielding a genotyping completion rate of
94.3% for 10 DRD3 SNPs for all included patients.
Genotypes were determined by investigators blinded
for clinical diagnoses and treatment response/
remission status.
Statistical analyses
Hardy–Weinberg equilibriumwas examined using the
program Finetti provided as an online source (http://
ihg.gsf.de/cgi-bin/hw/hwa1.pl). LD for DRD3 SNPs
(Dk and r2) was calculated using Haploview 4.2 (Broad
Institute, USA).
Pre-post ECT HAMD score diﬀerence was normally
distributed as assessed by the Kolmogorov–Smirnov
test. Homoscedasticity was veriﬁed by Levene’s test
for homogeneity of variances. Associations between
individual DRD3 SNPs and categories of response
(yes vs. no) and remission (yes vs. no) were estimated
by Pearson x2 test. Odds ratios (ORs) were calculated
using logistic regression analyses for the association
between response to treatment and remission and
genotypes of all DRD3 SNPs for dominant and re-
cessive models of inheritance, respectively. Corrected
p values were reported according to Benjamini &
Hochberg’s (1995) method [false discovery rate (FDR)]
in case signiﬁcant p values were discovered. Logistic
regression analyses were adjusted for age, gender
(borderline signiﬁcance) HAMD-21 baseline score,
lifetime duration of antidepressant treatment for
major depressive disorder (MDD) and lifetime dur-
ation of MDD episodes since these variables inﬂu-
enced response/remission to ECT treatment (50%
response and remission as deﬁned above in this study;
see Table 1). Conversely, the variables family history
for psychiatric illnesses, lifetime number of depressive
episodes, duration of current episode, lifetime number
of treatment cycles for MDD, elapsed time between
admission and ECT, duration of current hospitaliz-
ation, concomitant treatment with neuroleptics, fre-
quency of lifetime ECT treatments, number of single
ECT treatments during current treatment cycle and
initial stimulation intensity were without impact on
response/remission after ECT as deﬁned above (data
not shown) and were therefore not considered as
covariates for further analyses. In these logistic re-
gression models, the genotype with the lowest stat-
istical chance of response or remission was regarded
as reference. In addition to the ORs, the corresponding
95% conﬁdence interval and the p values are given. To
reduce computational demands and because of a
relatively small sample size, haplotypes were analysed
using the ‘sliding window’ approach with a three-
marker window size. Haplotypes were inferred using
the expectation maximization algorithm from un-
phased genotype data and a global test of haplotype
association was initially performed taking the most
common haplotype as baseline and comparing all
other haplotypes simultaneously. Statistically signiﬁ-
cant haplotypes were then explored individually and
tested for potential confounders such as age, gender,
HAMD-21 baseline score, lifetime duration of anti-
depressant treatment for MDD and lifetime duration
of MDD episodes. All associations were assessed
under dominant and recessive models of inheritance,
and Akaike’s Information Criterion was used for se-
lecting among models (Akaike, 1974). Three SNPs
identiﬁed to be individually associated with ECT re-
sponse/remission were set to create the haplotypes
because of computational limitations and decreasing
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frequency of longer haplotypes. All computations
were performed using SimHap v. 1.0.2 software
(Carter et al. 2008). All statistical analyses were per-
formed using Stata 11.0 (StataCorp, USA).
Power calculation
The available sample sizes had an 80% power to detect
an OR of approximately 0.2 or 3.5 for the association of
the risk allele with treatment response and remission
after ECT treatment in major depression. It was as-
sumed that a=0.05. Calculations were performed by
using the PS: Power and Sample Size Calculation v. 3.0
software (Biostat, USA).
fMRI methods
We analysed data of two independent samples of
acutely depressed in-patients available from previous
studies on emotion processing in depression (see be-
low). Each sample was presented with a diﬀerent
emotion processing paradigm, with both paradigms,
however, involving subliminally presented happy and
negative facial expressions. The same subliminal
presentation of happy faces has already been em-
ployed in a previous study investigating the eﬀect of
cannabinoid receptor 1 (CNR1) gene on the processing
of happy faces and was shown to reliably engage
subcortical structures such as the ventral striatum
(Domschke et al. 2008). The total number of patients
was n=54 (see Table 2 for details). All patients were
diagnosed by means of a structured clinical interview
(SCID-I) according to DSM-IV criteria (Wittchen et al.
1997), were right-handed, aged 18–60 yr, of Caucasian
background and had no neurological abnormalities
or magnetic resonance imaging contraindications.
Further exclusion criteria were any history of sub-
stance abuse and intake of mood stabilizers, neuro-
leptic drugs, psychostimulants, bupropione or
benzodiazepines. Patients were scanned shortly after
admission while being acutely depressed (HAMD
score >18). All patients were under antidepressant
treatment, which was coded in terms of dose and
treatment durations into medication levels 1–4, ac-
cording to the suggestions of Sackeim (2001).
Table 2. Sociodemographic and clinical characteristics of both functional magnetic resonance imaging samples dependent on
rs3732790 genotype (AA vs. T allele carriers)
Sample 1 (n=31) Sample 2 (n=23)
AA (n=7) T carriers (n=24) p value* AA (n=5) T carriers (n=18) p value*
Age (yr¡S.E.) 36.2¡12.1 38.2¡13.1 0.73 41.8¡6.9 38.9¡11.4 0.60
Gender 0.98 0.54
Male 2 7 2 10
Female 5 17 3 8
Age of onset (yr¡S.E.) 29.9¡13.2 27.2¡11.4 0.60 37.2¡11.5 31.9¡11.9 0.39
Number of episodes 4.7¡6.7 4.7¡4.7 0.99 2.2¡1.6 3.2¡2.4 0.38
HAMD 21.4¡4.1 22.7¡3.5 0.42 25.2¡6.3 24.7¡4.5 0.85
Verbal intelligencea 118.3¡20.3 115.9¡12.3 0.72 114.5¡8.5 111.2¡14.3 0.67
Antidepressant levelb 2.2¡1.4 2.5¡1.2 0.50 2.4¡1.3 2.8¡1.1 0.51
(Es-)Citalopram 2 2 1 3
Venlafaxin 2 8 1 3
Mirtazapin 2 5 1 3
Tricyclic 1 0 0 1
Venlafaxin+mirtazapine 0 5 2 1
Citalopram+mirtazapine 0 1 0 1
Fluoxetine 0 1 0 1
Duloxetine 0 2 0 1
Reboxetine 0 0 0 2
Sertraline 0 0 0 2
HAMD, Hamilton Rating Scale for Depression.
* According to t tests or Pearson x2 tests.
aMWT-B, Lehrl (1995).
b According to Sackeim (2001) : levels 1–2 represent antidepressant treatment<4 wk and/or low-dose antidepressant treatment,
whereas levels 3–4 represent antidepressant treatment>4 wk in moderate to high doses.
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The two fMRI paradigms were designed to assess
automatic neural responses to facial expressions. The
paradigms shared several similarities (identical facial
stimuli and the same backward-masking procedure of
the emotional faces with 33 ms presentation time). All
T2* functional imaging data were acquired with a 3 T
scanner (Gyroscan Intera 3 T; Philips Medical
Systems, USA) and functional data were processed
with Statistical Parametric Mapping (SPM5; Wellcome
Department of Cognitive Neurology, UK). Standard
pre-processing procedures were applied (motion
correction, normalization to standard Montreal
Neurological Institute (MNI) space and smoothing
with a 6-mm full width half maximum (FWHM).
Both fMRI samples were genotyped for those DRD3
SNPs associated with ECT treatment response.
Sample 1 : Datasets of 31 patients with complete
genotype and fMRI data were analysed. Technical
details of the fMRI paradigm have been reported pre-
viously (Baune et al. 2010; Dannlowski et al. 2007,
2008 ; Domschke et al. 2010). Brieﬂy, facial stimuli
consisted of sad, angry, happy and neutral expressions
(Ekman & Friesen, 1976). Subjects were presented with
alternating 30 s epochs of a face category or a no-face
stimulus (a grey rectangle). In a passive viewing task,
facial stimuli were presented twice per second for
33 ms in a random sequence directly followed by a
467 msmask depicting a neutral face of the same actor.
Each emotion epoch was preceded by a no-face epoch
and was presented twice, resulting in a total presen-
tation time of 8 min. Volumes consisting of 25 axial
slices were acquired (matrix 128r128, resolution
1.75r1.75r3.5 mm; TR=3 s, TE=30 ms, FA=90x)
160 times in blocked design, 10 times per condition. To
optimize the following normalization procedures, the
same sequence parameters were used to cover the
whole brain with 43 slices. The ﬁrst (individual) level
analysis was performed by modelling the diﬀerent
conditions (angry, sad, happy and neutral) as vari-
ables within the general linear model (modelled with
a canonical haemodynamic response function). The
motion parameters were entered as additional re-
gressors of no interest. For each patient, two contrast
images were generated: happy-no face baseline and
negative (angry and sad) faces-no face baseline.
Sample 2 : Datasets of 21 patients had complete
genotype and fMRI data. The paradigm used in sam-
ple 2 has been described previously (Dannlowski et al.
2010; Reker et al. 2010; Suslow et al. 2009, 2010). Facial
stimuli consisted of sad, happy and neutral ex-
pressions of 10 individuals (Ekman & Friesen, 1976).
Emotional and neutral faces were presented for 33 ms
and masked by neutral faces of the same individuals.
In total, 80 trials were shown: 20 with sad, 20 with
happy and 20 with neutral prime faces ; in 20 trials no
prime faces were presented. Faces were shown in two
ﬁxed pseudo-random sequences with the restriction of
no repetition of an individual and no more than one
repetition of a prime condition on consecutive trials.
Each trial lasted 9 s. A ﬁxation cross presented for
800 ms preceded a prime face shown for 33 ms, which
was followed by the corresponding neutral face mask,
presented for 467 ms. A blank screen followed for
7.700 ms. During this time period, subjects had to
evaluate whether the neutral (mask) face expressed
rather negative or positive feelings, by pressing one
of four buttons (x1.5, x0.5, +0.5, +1.5). In each
hand, participants held a ﬁbre-optic response pad
with two buttons (the positive or the negative re-
sponse keys). Volumes consisting of 40 axial slices
were acquired (matrix 64r64, resolution 3.5r3.5r
3.5 mm; TR=3 s, TE=30 ms, FA=90x). An event-
related analysis design was used. Brain responses to
the prime stimulus categories (sad, happy, neutral, no
face) were isolated by convolving a vector of onset
times of the emotional and neutral primes and the no-
face condition with a canonical haemodynamic re-
sponse function. The motion parameters were entered
as additional regressors of no interest. As in the ﬁrst
paradigm, the contrast images were generated for
subliminal happy-no face baseline and subliminal
negative-no face baseline for each patient. The no-face
baseline was chosen in both samples for two reasons.
Depressed patients were reported to show emotion-
processing biases for faces, including neutral faces,
which they perceive negatively (e.g. Dannlowski et al.
2006; Leppa¨nen et al. 2004). Therefore, a neutral face
baseline could be problematic if it is processed more
like a negative face condition. Furthermore, in a pre-
vious imaging genetics study of our group investigat-
ing genetic eﬀects on striatal responsiveness to
masked happy faces in depressed patients (Domschke
et al. 2008), the no-face baseline was also employed for
the same reason. Hence, we opted for maintaining
the same baseline for comparability reasons across
studies.
For both samples, the resulting ﬁrst level contrast
images were then included in a second level random
eﬀects group analysis of genotype eﬀects on the pro-
cessing of happy and negative faces. A ventral stri-
atum mask was generated as region of interest (ROI)
according to the suggestions of Forbes et al. (2009a, b).
The WFU PickAtlas Toolbox (Maldjian et al. 2003) was
used to create a sphere at Talairach coordinates x=0,
y=10, z=x10 with a radius of 20 mm, which in-
cluded the bilateral nucleus accumbens (O’Doherty
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et al. 2004). The ROI contained 4169 voxels
(2r2r2 mm) or 33r352 mm3). To control for mul-
tiple statistical testing, we maintained a cluster level
false–positive detection rate at p<0.05 using a voxel
threshold of p<0.01 with a cluster (k) extent empiri-
cally determined byMonte Carlo simulations (n=1000
iterations), by means of the AlphaSim procedure
(Forman et al. 1995), implemented in the REST toolbox
(http://restfmri.net/forum/index.php). The empiri-
cally determined cluster threshold was k=44 voxels
for the ventral striatum mask.
Results
Table 1 presents sociodemographic and clinical
characteristics of the overall sample as well as across
the patient groups stratiﬁed for post-ECT response
and remission status. Age (for response and re-
mission), lifetime duration of antidepressant treat-
ment, lifetime duration of depression and HAMD-21
baseline score (for response only) showed signiﬁcant
diﬀerences across response/remission status after
ECT, while gender showed borderline signiﬁcance for
response. Concomitant psychotropic (antidepressant/
neuroleptic/anxiolytic) medication, number of ECT
courses, duration of ECT treatment and initial stimu-
lation intensity had no eﬀect on response or remission.
Hardy–Weinberg criteria were fulﬁlled for geno-
type distributions of all 10 investigated polymor-
phisms in the overall sample. Due to complete LD
between rs324026 and rs324028 (r2=1.0), one of the
SNPs (rs324028) was excluded from further analyses.
LD between the remaining nine SNPs can be taken
from Fig. 1 (r2 range 0.08–0.98).
Pharmacogenetic results
Table 1 shows signiﬁcant associations between DRD3
SNPs and response and remission under ECT. Out of
nine individual SNPs, three SNPs (rs3732790,
rs3773679, rs9817063) were signiﬁcantly associated
both with response (rs3732790: uncorrected p=0.033;
rs3773679: uncorrected p=0.018; rs9817063: un-
corrected p=0.016) and remission (rs3732790: un-
corrected p=0.05 ; rs3773679: uncorrected p=0.047;
rs9817063: uncorrected p=0.022). In order to further
explore the nature of the three overall signiﬁcant as-
sociations between single DRD3 SNPs and response
and remission, respectively, adjusted logistic re-
gression analyses were performed to obtain genotype
speciﬁc associations for dominant and recessive
models of inheritance, as shown in Table 3 for re-
sponse and Table 4 for remission.
While adjusted analyses revealed no signiﬁcant as-
sociations between any of the nine DRD3 SNPs and
treatment response (see Table 3 for details), Table 4
presents signiﬁcant associations between remission
and rs3732790 and rs3773679, respectively : rs3732790T
allele (uncorrected p=0.009) and rs3773679 G allele
(uncorrected p=0.009) carriers displayed a higher
likelihood to achieve remission, when applying a re-
cessive model of inheritance. Under a dominant model
of inheritance, signiﬁcant association of the rs9817063
and remission was observed (uncorrected p=0.009).
However, only association between rs3732790/
rs3773679 and remission withheld correction for test-
ing of multiple hypotheses (FDR) (see Table 4 for de-
tails). Finally, haplotype analyses including these
three SNPs showed no signiﬁcant associations either
with response or remission (see Table 5).
fMRI results
Sample 1 : Bilateral ventral striatum activation was ob-
served in response to happy faces (x=10, y=x4,
z=x2, extending to x=16, y=10, z=0 ; Z=3.94 ; un-
corrected p=0.00004; cluster level corrected p=0.022;
cluster size k=56 ; x=x12, y=x4, z=x8, extending
to x=x16, y=4, z=x6 ; Z=3.40 ; uncorrected
p=0.0003 ; cluster level corrected p=0.001 ; cluster size
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Fig. 1. R2-based linkage disequilibrium (LD) of the presently
investigated nine single nucleotide polymorphisms (SNPs) in
the DRD3 gene region as retrieved from HapMap for the
Central Europeans, Utah (CEU) population (International
HapMap Consortium, 2003).
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k=98). However, in the negative condition, the stron-
gest cluster just failed to reach the cluster threshold
(k=40, cluster-corrected p=0.063).
Sample 2 : Again, bilateral ventral striatum acti-
vation was observed in response to happy faces
(x=x14, y=0, z=x2, Z=3.41 ; uncorrected
p=0.0003 ; cluster level corrected p=0.022 ; cluster size
k=56 ; x=18, y=4, z=x6 ; Z=2.90 ; uncorrected
p=0.0019 ; cluster level corrected p=0.034 ; cluster size
k=51). Also in sample 2 in the negative contrast, two
small clusters did not reach the cluster threshold.
Both fMRI samples were genotyped for those DRD3
SNPs associated with ECT treatment response
(rs3732790, rs3773679 and rs9817063). As in the overall
sample (r2=0.98), in both fMRI samples, rs3732790
and rs3773679 were in high LD and only one patient in
sample 1 had a divergent allelic distribution for the
two SNPs. Due to the grouping of AT/TT vs. AA
genotypes (see below) this subject would still be in
the same genotype group for both SNPs and the
fMRI statistics were therefore identical. Thus, only
rs3732790 and rs9817063 were used for further analy-
ses. Corresponding to signiﬁcant association between
remission and rs3732790 AT/TT vs. AA genotypes,
patients in the fMRI samples were grouped into AA
risk genotype carriers and carriers of at least one pro-
tective T allele. Accordingly, for rs9817063, subjects
were grouped into CC risk genotype carriers and car-
riers of at least one protective T allele.
Sample 1 : Genotyping for rs3732790 yielded seven
AA, 19 AT and ﬁve TT carriers (Hardy–Weinberg cri-
teria fulﬁlled, p=0.29). Carriers of rs3732790T alleles
Table 3.Multivariate association of DRD3 single nucleotide polymorphisms (SNPs) with response after electroconvulsive
therapy treatment in major depression
SNP Genotype
Dominant model Recessive model
OR 95% CI p AIC OR 95% CI p AIC
rs3732790 TT – – – 102
n.s.
– – –
102
n.s.TA
0.44 0.12–1.67 0.227
AA 0.43 0.12–1.53 0.193
rs9817063 CC – – – 101
n.s.
– – –
103
n.s.CT
2.87 0.85–9.65 0.100
TT 1.31 0.33–5.19 0.698
rs324035 CC – – – 103
n.s.
– – –
104
n.s.CA
0.64 0.21–1.90 0.418
AA 1.12 0.07–17.30 0.936
rs3773679 GG – – – 103
n.s.
– – –
102
n.s.GA
0.59 0.17–2.08 0.415
AA 0.43 0.12–1.53 0.193
rs167770 AA – – – 103
n.s.
– – –
103
n.s.AG
1.77 0.59–5.31 0.307
GG 2.74 0.17–43.31 0.473
rs6280 TT – – – 103
n.s.
– – –
103
n.s.TC
1.46 0.51–4.15 0.478
CC 1.42 0.24–8.46 0.697
rs324026 TT – – – 103
n.s.
– – –
103
n.s.TC
1.64 0.57–4.74 0.361
CC 1.42 0.24–8.46 0.697
rs1800828 GG – – – 101
n.s.
– – –
104
n.s.GC
2.31 0.75–7.11 0.145
CC 1.09 0.16–7.51 0.929
rs7638876 TT – – – 103
n.s.
– – –
103
n.s.TC
1.64 0.57–4.74 0.361
CC 1.57 0.28–8.83 0.611
OR, Odds ratio ; CI, conﬁdence intervals ; AIC, Akaike’s Information Criterion ; n.s., non-signiﬁcant model.
Adjusted for age, gender, Hamilton Rating Scale for Depression (HAMD)x21 baseline score, lifetime duration of antidepressant
treatment for major depressive disorder (MDD) and lifetime duration of MDD episodes.
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demonstrated increased neural responsiveness in two
clusters within the bilateral ventral striatum in re-
sponse to subliminally presented happy faces (x=2,
y=16, z=6, extending to x=14, y=20, z=x2;
Z=4.37 ; uncorrected p<0.00001 ; cluster level cor-
rected p=0.002; cluster size k=89 and x=x16, y=4,
z=x8 ; Z=3.93 ; uncorrected p=0.00004 ; cluster level
corrected p=0.040 ; k=48) (see also Fig. 2). There was
no signiﬁcant association of rs3732790 and striatal re-
sponsiveness to negative faces.
Sample 2 : Genotyping for rs3732790 yielded ﬁve
AA, 11 AT and ﬁve TT carriers (Hardy–Weinberg cri-
teria fulﬁlled, p=1.0). A highly similar result has
been found with rs3732790T allele carriers showing
increased responsiveness in the bilateral ventral stri-
atum in response to subliminally presented happy
faces (x=x10, y=8, z=0 ; Z=3.29 ; uncorrected
p=0.0005 ; cluster level corrected p=0.040 ; k=48 and
x=12, y=18, z=0; Z=2.99 ; uncorrected p=0.0014;
cluster level corrected p=0.023 ; k=55) (Fig. 2). Again,
there was no association of rs3732790 and striatal re-
sponsiveness to negative faces.
There was no signiﬁcant eﬀect of rs9817063 geno-
type on ventral striatum activity during the processing
of either negative or positive facial expressions in
either sample that survived our rigorously corrected a
threshold when CC genotype carriers were compared
with T allele carriers.
Table 4. Multivariate association of DRD3 single nucleotide polymorphisms (SNPs) with remission after electroconvulsive
therapy treatment in major depression
SNP Genotype
Dominant model Recessive model
OR 95% CI p pcor AIC OR 95% CI p pcor AIC
rs3732790 TT – – – – 121
n.s.
– – – –
115
0.006TA
0.53 0.17–1.64 0.271
0.301
AA 0.20 0.06–0.67 0.009 0.045
rs9817063 CC – – – – 115
0.007
– – – –
122
n.s.CT
4.60 1.45–14.61 0.009 0.090
TT 1.03 0.31–3.40 0.959 0.959
rs324035 CC – – – – 120
n.s.
– – – –
121
n.s.CA
1.89 0.67–5.29 0.228 0.285
AA 4.10 0.26–64.34 0.315 0.394
rs3773679 GG – – – – 121
n.s.
– – – –
115
0.006GA
0.67 0.23–1.98 0.471 0.471
AA 0.20 0.06–0.67 0.009 0.045
rs167770 AA – – – – 119
n.s.
– – – –
121
n.s.AG
2.29 0.83–6.28 0.108 0.154
GG 2.70 0.19–38.90 0.465 0.517
rs6280 TT – – – – 119
n.s.
– – – –
120
n.s.TC
2.37 0.90–6.24 0.080 0.133
CC 3.78 0.69–20.63 0.124 0.207
rs324026 TT – – – – 118
n.s.
– – – –
119
n.s.TC
2.68 0.99–7.23 0.052 0.130
CC 3.78 0.69–20.63 0.124 0.248
rs1800828 GG – – – – 118
n.s.
– – – –
121
n.s.GC
2.72 0.96–7.73 0.060 0.120
CC 2.61 0.43–15.63 0.294 0.420
rs7638876 TT – – – – 118
n.s.
– – – –
119
n.s.TC
2.68 0.99–7.23 0.052 0.260
CC 4.19 0.80–21.88 0.079 0.263
OR, Odds ratio ; CI, conﬁdence intervals ; pcor, corrected p value for nine comparisons by Benjamini & Hochberg (1995) method;
AIC, Akaike’s Information Criterion ; n.s., non-signiﬁcant model.
Adjusted for age, gender, Hamilton Rating Scale for Depression (HAMD)x21 baseline score, lifetime duration of antidepressant
treatment for major depressive disorder (MDD) and lifetime duration of MDD episodes.
Bold indicates signiﬁcant p values ati0.05.
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Discussion
In the present study, signiﬁcant association of DRD3
SNPs rs3732790, rs3773679 and rs9817063 with re-
sponse and remission, respectively, after ECT was ob-
served in a sample of patients with treatment-resistant
major depression. Particularly, the rs3732790T,
rs3773679 G and rs9817063T alleles seem to exert a
beneﬁcial eﬀect with regard to remission under ECT,
with, however, only the association between
rs3732790/rs3773679 and remission surviving correc-
tion for multiple testing. The functional DRD3 Bal1
(Ser9Gly) polymorphism (rs6280), which was pre-
viously found to be associated with the categorical di-
agnosis of depression (Dikeos et al. 1999; but : Serretti
et al. 1999, 2000), but not with antidepressant eﬀects of
either lithium or total sleep deprivation in mood dis-
orders (Benedetti et al. 2003; Serretti et al. 1998), was
not identiﬁed to diﬀerentially inﬂuence response/
remission to ECT.
The present fMRI data reveal a remarkable consist-
ency regarding the neurobiological eﬀect of DRD3
gene variation associated with response and/or
remission to ECT. In two independent samples,
carriers of the protective rs3732790T allele (which was
in almost total LD with the rs3773679 G allele) showed
stronger automatic striatal responsiveness to happy
facial expressions compared with AA homozygotes,
who displayed an increased risk of non-response or
non-remission under ECT. There is considerable
neuropsychological and neurobiological evidence that
the processing of happy facial expressions is impaired
or biased in major depression, which was proposed
to be of importance for the course of disease (e.g.
Gur et al. 1992; Persad & Polivy, 1993 ; Suslow et al.
2004). Furthermore, several fMRI studies revealed re-
duced striatal reactivity to positive or rewarding
stimuli in depressed patients compared with healthy
controls (Lawrence et al. 2004; Pizzagalli et al. 2009a)
and stronger ventral striatum responsiveness was
suggested as a potential marker of treatment success
(Forbes et al. 2010). Taken together, these data suggest
that striatal hypo-responsiveness to facial expressions
of happiness might represent a neurobiological sub-
strate of depression and depression persistence, at
least partly conferred by the DRD3 rs3732790 AA
genotype. Importantly, the rs3732790 AA genotype
did not alter the neural response to negative faces,
Table 5.Multivariate association of DRD3 haplotypes with response/remission after electroconvulsive therapy treatment in
major depression
Outcome SNP Haplotype Copy
Dominant model Recessive model
OR 95% CI p AIC OR 95% CI p AIC
Response rs3732790 ACA 0 – – – 102
n.s.
– – –
103
n.s.1
1.35 0.20–6.08 0.424
2 0.61 0.18–2.00 0.413
rs9817063 TTG 0 – – – 103
n.s.
– – –
104
n.s.1
1.10 0.34–3.39 0.718
2 1.16 0.25–5.35 0.853
rs3773679 TCG 0 – – – 103
n.s.
– – –
–1 0.78 0.13–3.81 0.545
2 – – –
Remission rs3732790 ACA 0 – – – 121
n.s.
– – –
120
n.s.1
1.56 0.43–4.89 0.510
2 2.22 0.64–7.79 0.211
rs9817063 TTG 0 – – – 121
n.s.
– – –
121
n.s.1
0.78 0.20–2.61 0.526
2 0.54 0.17–1.71 0.292
rs3773679 TCG 0 – – – 122
n.s.
– – –
–1 0.99 0.21–4.11 0.705
2 – – –
SNP, Single nucleotide polymorphisms ; Copy, number of copies of the haplotype ; OR, odds ratio ; CI, conﬁdence intervals ; AIC,
Akaike’s Information Criterion ; n.s., non-signiﬁcant model.
Adjusted for age, gender, Hamilton Rating Scale for Depression (HAMD)x21 baseline score, lifetime duration of antidepressant
treatment for major depressive disorder (MDD) and lifetime duration of MDD episodes.
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underscoring its speciﬁc eﬀect on reward processing.
While we investigated the whole ventral striatum and
not speciﬁcally the nucleus accumbens, the nucleus
accumbens coordinates reported in a previous study
focusing on the nucleus accumbens were included in
the clusters found in our analyses (O’Doherty et al.
2004).
The following limitations have to be considered
while interpreting the present results. The function-
ality of the present associated polymorphisms is still
unknown and remains to be elucidated in future
studies. Also, no dopamine levels have been measured
in the present sample, which could have helped in
deﬁning the functional relevance of DRD3 gene vari-
ation. Furthermore, the present selection of tagging
SNPs covering only 95.4% of the DRD3 gene does not
allow for an utterly comprehensive evaluation of
all DRD3 variation. In general, as ECT has multiple
known and assumed mechanisms of action with e.g.
evidence for ECT to alter adrenergic and serotonergic
transmission as well as several subtypes of 5-HT
receptors and neurotrophic factors in the central
nervous system (as reviewed by Wahlund & von
Rosen, 2003 ; Cassidy et al. 2010), DRD3 gene inﬂuence
on ECT response has to be interpreted within a very
complex framework of neurotransmission and
neural networks. Particularly, a signiﬁcant interaction
between the dopamine D3 receptor and e.g. the brain-
derived neurotrophic factor (BDNF) and the sero-
tonergic system has been described previously
(Chernoloz et al. 2009; Jo¨nsson et al. 1996; Takahashi
et al. 2008). In this respect, it has to be noted that the
present results were not corrected for potentially con-
founding inﬂuences of further polymorphisms within
the dopaminergic system previously found to be as-
sociated with ECT response, such as COMT Val158Met
or DRD2 C957T (Anttila et al. 2008; Domschke et al.
2009; Huuhka et al. 2008), BDNF gene variation
(Fernandes et al. 2009; Huuhka et al. 2007) or poly-
morphisms impacting ventral striatum responsiveness
to emotional stimuli such as DAT 40-bp 3kVNTR or
CNR1 rs1049353 (Chakrabarti et al. 2006; Domschke
et al. 2008; Hahn et al. 2011). Additionally, since 71.2%
of the present investigated patients concomitantly re-
ceived antidepressant pharmacotherapy, 79.8% ad-
junct neuroleptic medication and 20.2% anxiolytic
agents as invariably done in daily clinical practice, the
present eﬀect – although not statistically signiﬁcant
in our sample – could be inﬂuenced by concomitant
antidepressant (Baghai et al. 2006), antipsychotic
–9 –7 –5 –3 –1
–9 –7 –5 –3 –1
(a)
(b)
Fig. 2. Axial slices depicting the eﬀect of rs3732790 (T carriers>AA homozygotes) on neural responsiveness to subliminally
presented happy faces within the ventral striatum in two independent patient samples. (a) Sample 2 (n=21) ; (b) sample 1
(n=31). The clusters are signiﬁcant at p<0.01 with a cluster extend threshold of k=44.
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(Nothdurfter et al. 2006) or anxiolytic (Jha & Stein,
1996) pharmacotherapy and might therefore not be
speciﬁc for ECT. Also, given no overlap between the
pharmacogenetic sample being treated with ECT and
the imaging genetic samples it cannot be evaluated
whether BOLD signal in the ventral striatum during
emotional processing was correlated to some ECT
measures, such as the number of sessions of ECT or to
remission during ECT treatment. The sample under
study has not been evaluated for Axis II disorders,
which might have confounded the present results (e.g.
Feske et al. 2004). Furthermore, a large age range
(23–81 yr) of the present sample including elderly
patients has to be acknowledged with a signiﬁcantly
better response to ECT in older patients, which is in
line with a multi-site longitudinal study (CORE)
showing older age to confer a greater likelihood of
achieving remission under ECT (O’Connor et al. 2001)
and another study reporting even the oldest depressed
patients to respond to ECT equally well or even better
than younger patients (Tew et al. 1999). However,
several other studies failed to demonstrate an inﬂu-
ence of age on ECT eﬀectiveness (Birkenha¨ger et al.
2010; Damm et al. 2010). Finally, taking into account
the OR usually found by pharmacogenetic studies in
major depression, the power of the present study to
detect associations with remission is quite low.
Consequently, replication studies in larger, indepen-
dent samples are required to draw a ﬁrm conclusion.
While this is also true for the fMRI part, particularly
with regard to each single fMRI sample, to the best of
our knowledge this is the largest functional imaging
genetics study employing depressed patients.
In summary, the present ﬁndings provide prelimi-
nary evidence for an impact of DRD3 gene variation
on ECT response. Alleles associated with a more
favourable response to ECT were also associated with
stronger automatic striatal responsiveness to positive
social cues, suggesting a potential neurobiological
underpinning for the beneﬁcial eﬀects of these alleles.
Provided replication in independent samples, these
results might aid in elucidating the neurobiological
mechanism of ECT eﬀectiveness in more detail and
might thereby potentially contribute to more neuro-
biologically informed treatment decisions in favour of
ECT in conjunction with pharmacological treatment in
the future.
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